Patents by Inventor Ginger RAKESTRAW
Ginger RAKESTRAW has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124597Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: August 22, 2023Publication date: April 18, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20240092907Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.Type: ApplicationFiled: February 1, 2023Publication date: March 21, 2024Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Andy X. Deng, Lin Hui Su, Ginger Rakestraw
-
Patent number: 11926673Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: January 19, 2022Date of Patent: March 12, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Patent number: 11795231Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: February 11, 2022Date of Patent: October 24, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Patent number: 11773178Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: January 31, 2022Date of Patent: October 3, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Patent number: 11708405Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: December 27, 2019Date of Patent: July 25, 2023Assignee: BRISTOL-MYERS QUIBB COMPANYInventors: Mohan Srinivasan, Shrikant Deshpande, Qihong Zhao, Huadong Sun, Ginger Rakestraw, Guodong Chen, Richard Y. Huang, Steven Sheriff, Cristian Rodriguez, John P. Throup, Rose A. Dibella
-
Patent number: 11603406Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.Type: GrantFiled: March 13, 2018Date of Patent: March 14, 2023Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Andy X. Deng, Lin Hui Su, Ginger Rakestraw
-
Publication number: 20220169742Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: February 11, 2022Publication date: June 2, 2022Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, Jr., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20220153856Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: January 31, 2022Publication date: May 19, 2022Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20220144962Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: January 19, 2022Publication date: May 12, 2022Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20220073617Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.Type: ApplicationFiled: July 10, 2019Publication date: March 10, 2022Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Michael Quigley, Hadia Lemar, Akbar Nayeem
-
Patent number: 11261258Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: November 18, 2019Date of Patent: March 1, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Patent number: 11254750Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: October 26, 2020Date of Patent: February 22, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Publication number: 20210054090Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: October 26, 2020Publication date: February 25, 2021Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20210017283Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.Type: ApplicationFiled: March 19, 2019Publication date: January 21, 2021Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova
-
Publication number: 20200190180Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: ApplicationFiled: December 27, 2019Publication date: June 18, 2020Inventors: Mohan SRINIVASAN, Shrikant DESHPANDE, Qihong ZHAO, Huadong SUN, Ginger RAKESTRAW, Guodong CHEN, Richard Y. HUANG, Steven SHERIFF, Cristian RODRIGUEZ, John P. THROUP, Rose A. DIBELLA
-
Publication number: 20200157233Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: November 18, 2019Publication date: May 21, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20200055936Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.Type: ApplicationFiled: March 13, 2018Publication date: February 20, 2020Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Andy X. Deng, Lin Hui Su, Ginger Rakestraw
-
Patent number: 10556948Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: November 30, 2016Date of Patent: February 11, 2020Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Mohan Srinivasan, Shrikant Deshpande, Qihong Zhao, Huadong Sun, Ginger Rakestraw, Guodong Chen, Richard Y. Huang, Steven Sheriff, Cristian Rodriguez, John P. Throup, Rose A. Dibella
-
Publication number: 20170158757Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: ApplicationFiled: November 30, 2016Publication date: June 8, 2017Inventors: Mohan SRINIVASAN, Shrikant DESHPANDE, Qihong ZHAO, Huadong SUN, Ginger RAKESTRAW, Guodong CHEN, Richard Y. HUANG, Steven SHERIFF, Cristian RODRIGUEZ, John P. THROUP, Rose A. DIBELLA